Netherlands Cancer Drugs Delayed

In the Netherlands, nearly all new cancer treatments approved in Europe are already being used in Germany—48 out of 51—highlighting a shocking delay caused by the Dutch system’s lengthy, price-focused approval process. While Germany negotiates prices swiftly within six months after approval, the Netherlands drags out decisions for an average of 655 days, often failing to reach agreements. This gap is costing patients time—and potentially lives—while treatments for deadly diseases like multiple myeloma are already saving lives across the border. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/82ee98ae8d2cf085